Recent pharmacological advancements have transformed the management of T2DM, with sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) becoming cornerstone therapies not only for glycemic control but also for cardiovascular risk reduction [4]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.